NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Thanks Senti! The general drift of what you say makes sense but like you I’m not aware of the details of mutations in GBM. There is some work on inter and intratumoral mutational heterogeneity that I’m looking at in regards to the theoretical effectiveness of targeted therapies that might touch tangential on GBM but it’s not the main focus.

In any case, there is evidence of DCs being able to deal with neoantigens — which makes sense since that’s one of the key roles they play!

More to come, as they say.